文献速递心力衰竭与心肌病

AAVrh.10hFXN 基因治疗用于 Friedreich 共济失调心肌病的非随机临床试验

AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

结果显示治疗总体耐受良好,心脏活检 FXN 蛋白升高、LVMI 下降或稳定、hs 肌钙蛋白 I 多下降,提示其可能成为 FA 心肌病的潜在治疗。

要点

  • 静脉 AAVrh.10hFXN 在 FA 心肌病患者中总体耐受良好,严重不良事件均可缓解。
  • 治疗后心脏活检 FXN 蛋白升高,LVMI 在多数患者中下降或稳定。
  • 血清 hs 肌钙蛋白 I 多数下降,支持初步探索性疗效信号。

核心结论

  • 静脉给予 AAVrh.10hFXN 耐受良好,并可能成为 FA 心肌病的潜在治疗,依据为探索性疗效终点的初步改善。

研究设计与样本

  • 干预为静脉给予 AAVrh.10hFXN,设 3 个剂量队列:1.8 × 10^11、5.6 × 10^11 和 1.2 × 10^12 载体基因组/千克体重。
  • 主要结局为安全性,同时评估心脏活检 FXN 蛋白水平、心脏磁共振来源的左心室质量指数(LVMI)和血清高敏(hs)肌钙蛋白 I 等探索性终点。

主要发现

  • 共发生 4 例严重不良事件,其中 3 例可能与泼尼松免疫抑制相关,1 例可能在治疗后 12 个月与载体相关的心肌炎,均缓解。
  • 8 例患者在治疗后 3 个月行心脏活检,心脏 FXN 水平升高(剂量队列 1 为 20%;队列 2 为 81%;队列 3 为 123%)。
  • 治疗后 LVMI 在 9 例患者中至少下降 10%,在 8 例患者中保持稳定。
  • 排除心肌炎患者后,治疗后血清 hs 肌钙蛋白 I 在 15 例患者中至少下降 10%,在 2 例患者中至少升高 10%。
  • 其他不良事件为短暂、非严重或与治疗无关。

临床怎么用

  • 对 FA 心肌病患者,可关注静脉 AAVrh.10hFXN 基因治疗这一在研策略,当前证据限于非随机小样本探索性试验,尚不能用于常规临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Friedreich ataxia (FA), a fatal, autosomal recessive disorder caused by pathogenic variants in the frataxin (FXN) gene, is characterized by progressive neurologic and cardiac disease, with cardiac disease being the major cause of death. Preclinical studies have demonstrated that systemic administration of AAVrh.10hFXN, an rh.10 serotype cardiotropic adenoassociated virus (AAV) vector expressing the normal human FXN coding sequence, reverses the cardiomyopathy in FXN-deficient mice. OBJECTIVE: To assess the safety and preliminary efficacy of administration of AAVrh.10hFXN to adults with FA cardiomyopathy. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial evaluates the pooled data of 2 independent, open-label, dose-escalation trials that used the same gene therapy vector and similar clinical protocols among patients with FA cardiomyopathy at academic medical centers. Data were collected from February 22, 2022, to October 4, 2025, for trial 1 and from February 14, 2023, to September 10, 2025, for trial 2 and analyzed together from November 5, 2025, to March 12, 2026. INTERVENTION: AAVrh.10hFXN, administered intravenously in 3 dose cohorts (1.8 × 1011, 5.6 × 1011, and 1.2 × 1012 vector genomes per kilogram of body weight). MAIN OUTCOMES AND MEASURES: In addition to safety as the primary outcome, multiple parameters of exploratory end points were assessed, including cardiac biopsy levels of FXN protein, cardiac magnetic resonance imaging-derived left ventricular mass index (LVMI), and serum high-sensitivity (hs) troponin I. RESULTS: Seventeen patients with FA cardiomyopathy (mean [SD] age, 25 [6] years; 11 [65%] female) were followed up for a mean (SD) of 20 (8) months. There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved. Other adverse events were transient, nonserious, or not treatment related. In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%). After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients. Excluding the patient with myocarditis, posttherapy values of serum hs troponin I were lower by at least 10% in 15 patients and higher by at least 10% in 2 patients. CONCLUSIONS AND RELEVANCE: Findings of this nonrandomized clinical trial suggest that intravenous administration of AAVrh.10hFXN was well tolerated and may be a potential treatment for FA cardiomyopathy, as evidenced by preliminary improvement in exploratory efficacy end points. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT05302271 and NCT05445323.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Crystal RG, Weinsaft JW, Kaminsky SM, et al. AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia: A Nonrandomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42307907. doi:10.1001/jamacardio.2026.1699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。